Efficacy and Safety of Platinum-Based Chemotherapy as First-Line Therapy for Metastatic Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials

BACKGROUND: Triple-negative breast cancer constitutes approximately 12%-17% of all breast cancer cases, and >33% of patients develop distant metastases. Systemic cytotoxic chemotherapy is the primary treatment for patients with metastatic triple-negative breast cancer; however, the role of first-...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Fei, Hou, Yu, Chen, Zhengting, Jiang, Jie, He, Xi, Xia, Yaoxiong, Cao, Ke, Chang, Li, Li, Wenhui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8120541/
https://www.ncbi.nlm.nih.gov/pubmed/33977814
http://dx.doi.org/10.1177/15330338211016369

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8120541/
https://www.ncbi.nlm.nih.gov/pubmed/33977814
http://dx.doi.org/10.1177/15330338211016369

Ejemplares similares